2022
An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol
Garakani A, Freire RC, Buono FD, Thom RP, Larkin K, Funaro MC, Salehi M, Perez-Rodriguez MM. An umbrella review on the use of antipsychotics in anxiety disorders: A registered report protocol. PLOS ONE 2022, 17: e0269772. PMID: 35709149, PMCID: PMC9202921, DOI: 10.1371/journal.pone.0269772.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsSelective serotonin reuptake inhibitorsSerotonin-norepinephrine reuptake inhibitorsUse of antipsychoticsLong-term riskAnxiety disordersReuptake inhibitorsUmbrella reviewSide effectsPanic disorderSystematic reviewNon-antipsychotic medicationsUse of quetiapineFirst-line treatmentSerotonin reuptake inhibitorsNorepinephrine reuptake inhibitorsEvidence of efficacyCommon psychiatric disordersTraditional pharmacologic treatmentTreatment of anxietyAdjunctive treatmentPharmacologic treatmentTricyclic antidepressantsAntipsychoticsPsychiatric disordersSocial anxiety disorder
2020
Systematic review of benzodiazepines for anxiety disorders in late life.
Gupta A, Bhattacharya G, Farheen SA, Funaro M, Balasubramaniam M, Young J, Tampi DJ, Tampi RR. Systematic review of benzodiazepines for anxiety disorders in late life. Annals Of Clinical Psychiatry 2020, 32: 114-127. PMID: 32343283.Peer-Reviewed Educational MaterialsMeSH KeywordsAgedAnxiety DisordersBenzodiazepinesHumansMiddle AgedRandomized Controlled Trials as TopicConceptsAnxiety disordersSystematic reviewOlder adultsTolerability of benzodiazepinesCochrane Central RegisterMild adverse effectsLater lifeEnglish-language articlesTreatment of anxietyLong-term useWeb of ScienceTolerability dataCentral RegisterControlled TrialsCochrane DatabaseOvid EmbaseLong-term benefitsOvid MEDLINEInclusion criteriaEligible articlesBenzodiazepinesDecreased anxietyStudy periodAdverse effectsTrials